Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

422
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
422
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

461
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
461
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

921
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
921
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

517
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
517

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Dermatology and therapy·2026
Same author

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis.

International journal of dermatology·2026
Same author

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2026

Related Experiment Video

Updated: Jul 19, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K

Talquetamab-Induced Grover's Disease.

Mindy Kresch, Sophie Guenin, Adnan Mubasher

    Journal of Drugs in Dermatology : JDD
    |August 9, 2023
    PubMed
    Summary

    Talquetamab, a new cancer therapy, can cause Grover's disease, a rare skin condition. This study documents this adverse drug reaction in patients treated with talquetamab.

    Area of Science:

    • Dermatology
    • Oncology
    • Pharmacology

    Background:

    • Talquetamab is a bispecific antibody targeting GPRC5D and CD3, used in multiple myeloma treatment.
    • Adverse drug reactions are common with novel cancer therapies.
    • Grover's disease (pruritic papular eruption) is a rare skin condition.

    Purpose of the Study:

    • To report a case of Grover's disease induced by talquetamab.
    • To highlight a previously undocumented adverse drug reaction associated with talquetamab therapy.

    Main Methods:

    • Case report of a patient who developed a pruritic papular eruption during talquetamab treatment.
    • Clinical and histological evaluation of the skin condition.

    Main Results:

    More Related Videos

    Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
    06:21

    Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

    Published on: May 10, 2024

    762
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.4K

    Related Experiment Videos

    Last Updated: Jul 19, 2025

    MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
    05:54

    MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

    Published on: December 13, 2017

    14.0K
    Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
    06:21

    Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

    Published on: May 10, 2024

    762
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.4K
    • The patient developed a generalized pruritic papular eruption consistent with Grover's disease.
    • The eruption resolved after discontinuation of talquetamab.
    • Skin biopsy confirmed the diagnosis of Grover's disease.

    Conclusions:

    • Talquetamab can induce Grover's disease as an adverse reaction.
    • Clinicians should be aware of this potential side effect in patients receiving talquetamab.
    • Further investigation may be needed to understand the mechanism of talquetamab-induced Grover's disease.